The First-In-Human Trial of the Humanised Monoclonal Antibody NNC 0151-0000-0000 Blocking the C5A Receptor (C5AR)

Trial Profile

The First-In-Human Trial of the Humanised Monoclonal Antibody NNC 0151-0000-0000 Blocking the C5A Receptor (C5AR)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2014

At a glance

  • Drugs Anti-C5a monoclonal antibody; Anti-C5a monoclonal antibody; NN 8209
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 09 Jul 2009 New trial record.
    • 13 Jun 2009 Interim results were reported at EULAR 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top